Rate My Professor Jiang Zhu

His research program combines computational modeling and experimental validation to address key biomedical challenges. Primary areas include antibody discovery using next-generation sequencing, scFv phage libraries, and computational tools for B-cell repertoire analysis; rational vaccine design via structural modeling and nanoparticle engineering for viruses like HIV-1, respiratory syncytial virus, metapneumovirus, influenza A, Ebola virus, SARS-CoV-2, hepatitis C virus, and Zika; and structure-function studies of macromolecular complexes using cryo-EM and other techniques. Key publications encompass "Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus" (Nature Communications, 2024), "Single-Component Multilayered Self-Assembling Protein Nanoparticles Displaying Extracellular Domains of Matrix Protein 2 as a Pan-influenza A Vaccine" (ACS Nano, 2023), "Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates" (Nature Communications, 2023), Ebola virus vaccines (Nature Communications, 2021), and SARS-CoV-2 vaccine candidates (Science Advances, 2021). Zhu has been honored with National Institute of Allergy and Infectious Diseases Merit Awards in 2010, 2011, and 2012 for vaccine development contributions. His innovations have yielded promising vaccine candidates advancing to preclinical and clinical stages, significantly impacting prophylactic strategies against infectious diseases.